Clinical trial
Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In…
NCT00484185 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00484185 |
|---|---|
| Title | Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B |
| Official title | Post Marketing Surveillance To Observe Safety And Efficacy Of BeneFIX In Patients With Hemophilia B |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hemophilia B |
| Intervention type | Drug |
| Interventions | BeneFIX (coagulation factor IX (recombinant)) |
| Enrollment | 183 |
| Start date | Aug 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Jun 8, 2007 |
| Last update posted | Aug 12, 2013 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: